Jae Eun Choi1, Tyler Werbel2, Zhenping Wang1, Chia Chi Wu1, Tony L Yaksh3, Anna Di Nardo4. 1. Department of Dermatology, University of California, San Diego, CA, USA. 2. School of Medicine, University of California, San Diego, CA, USA. 3. Department of Anesthesiology and Pharmacology, University of California, San Diego, CA, USA. 4. Department of Dermatology, University of California, San Diego, CA, USA. Electronic address: adinardo@ucsd.edu.
Abstract
BACKGROUND: Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown. OBJECTIVES: To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions. METHODS: Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections. RESULTS: Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers. CONCLUSIONS: These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.
BACKGROUND:Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown. OBJECTIVES: To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions. METHODS: Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections. RESULTS: Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers. CONCLUSIONS: These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.
Authors: Florian Schiemann; Ernst Brandt; Roland Gross; Buko Lindner; Jessica Mittelstädt; Christian P Sommerhoff; Jan Schulmistrat; Frank Petersen Journal: J Immunol Date: 2009-07-22 Impact factor: 5.422
Authors: Kenshi Yamasaki; Jürgen Schauber; Alvin Coda; Henry Lin; Robert A Dorschner; Norman M Schechter; Chrystelle Bonnart; Pascal Descargues; Alain Hovnanian; Richard L Gallo Journal: FASEB J Date: 2006-10 Impact factor: 5.191
Authors: Roshni Ramachandran; Marc J Marino; Snighdha Paul; Zhenping Wang; Nicholas L Mascarenhas; Sabine Pellett; Eric A Johnson; Anna DiNardo; Tony L Yaksh Journal: Toxins (Basel) Date: 2018-03-23 Impact factor: 4.546
Authors: Shiqun Zhang; Tara N Edwards; Virendra K Chaudhri; Jianing Wu; Jonathan A Cohen; Toshiro Hirai; Natalie Rittenhouse; Elizabeth G Schmitz; Paul Yifan Zhou; Benjamin D McNeil; Yi Yang; H Richard Koerber; Tina L Sumpter; Amanda C Poholek; Brian M Davis; Kathryn M Albers; Harinder Singh; Daniel H Kaplan Journal: Cell Date: 2021-03-24 Impact factor: 41.582